Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin® in metastatic pancreatic cancer. The two-stage, single arm, open label study in combination with gemcitabine enrolled approximately 35 patients at sites in the United States and India. The primary efficacy endpoint of the study is overall survival.
"We are pleased to have completed enrollment in this trial, and we expect to report preliminary results in the first half of 2012," said Rick Soni, President and Chief Operating Officer of Rexahn. "As a novel Akt protein kinase inhibitor, Archexin has the potential to develop into an important therapeutic for the treatment of pancreatic cancer, a disease with a low survival rate and limited treatment options."
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths